Pharmaceuticals, Biotechnology and Life Sciences
Innovent Biologics got approval from the National Medical Products Administration (NMPA) to start clinical trials for its IND application for IBI318, a recombinant fully human bispecific antibody targeting programmed cell death protein 1 (PD-1) and an undisclosed target for a tumor-associated antigen (TAA), in patients with hematological and advanced solid tumors.
U.S. Food and Drug Administration (FDA) approved AbbVie’s Imruvica (ibrutinib) combined rituximab (Rituxan) for treating adult patients with Waldenström’s macroglobulinemia (WM).
Innovent Biologics has started testing on patients its Tyvyt, fully human anti-PD-1 therapeutic monoclonal antibody, with generic name sintilimab injection, in combination with capecitabine and oxaliplatin, patients with advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (GC or GEJ).
Innovent Biologics has dosed the first patient in a phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies.
Basilea Pharmaceutica’s analysis of the registrational phase 2 study of potential of derazantinib in the treatment of FGFR-driven tumors, also confirmed the safety profile and tolerability of the drug candidate observed in previous clinical studies.
Cellular Biomedicine Group (CBMG) will begin picking the patients to test anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China.
Mirati Therapeutics and Bristol-Myers Squibb will work together on evaluating the combination of sitravatinib and nivolumab (OPDIVO), in Mirati’s planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.
AstraZeneca has reached a clinical development milestone with immuno-oncology candidate AZD4635, thus triggering a $15 million payment to its partner, Sosei Group.
4D pharma and The University of Texas MD Anderson Cancer Center will together work on testing 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings, the company said on Monday in a press release
Regeneron Pharmaceuticals and Sanofi restructure immuno-oncology agreement from 2015, where Regeneron retains full rights to all its other investigational immunooncology programsto, while Sanofi is able to independently chase own immuno-oncology programs.